VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Immune checkpoint inhibitors in MDS and AML

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses immune checkpoint inhibitors in myeloid malignancies. Dr Zeidan highlights different trials evaluating the use of MBG453 in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), including the STIMULUS-MDS1, STIMULUS-MDS2, STIMULUS-AML1 trials. Additionally, he outlines the ongoing trial of magrolimab in combination with azacitidine in MDS and AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter